Myocardial Triglyceride Content
MRS
Empagliflozin treatment led to a trend in decrease of MTG, measured via proton MRS, comparable in patients with HFrEF (adjusted mean treatment difference, −0.44% [95% CI, −0.97 to 0.08]; 